Medicenna Therapeutics (TSE:MDNA) Shares Down 2% – Time to Sell?

Medicenna Therapeutics Corp. (TSE:MDNA) shares fell 2% during trading on Friday . The stock traded as low as C$0.97 and last traded at C$0.98. 9,578 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 64,439 shares. The stock had previously closed at C$1.00.

Medicenna Therapeutics Stock Performance

The business has a 50 day moving average price of C$1.16 and a two-hundred day moving average price of C$1.64. The company has a debt-to-equity ratio of 0.88, a quick ratio of 4.65 and a current ratio of 11.40. The company has a market cap of C$73.32 million, a P/E ratio of -2.70 and a beta of 1.21.

Insider Activity

In other news, Senior Officer David Hyman acquired 20,000 shares of the firm’s stock in a transaction on Thursday, January 9th. The shares were purchased at an average price of C$1.45 per share, for a total transaction of C$29,000.00. Insiders own 22.57% of the company’s stock.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.